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Abstract
Background: Focal chondral defects of the knee are common. Several surgical techniques have been proposed for
the management of chondral defects: microfractures (MFX), osteochondral autograft transplantation (OAT),
autologous matrix-induced chondrogenesis (AMIC) and autologous chondrocyte implantation (ACI)—first
generation (pACI), second generation (cACI) and third generation (mACI). A Bayesian network meta-analysis was
conducted to compare these surgical strategies for chondral defects in knee at midterm follow-up.
Methods: This Bayesian network meta-analysis was conducted according to the PRISMA extension statement for
reporting of systematic reviews incorporating network meta-analyses of health care interventions. PubMed, Google
Scholar, Embase and Scopus databases were accessed in July 2021. All the prospective comparative clinical trials
investigating two or more surgical interventions for chondral defects of the knee were accessed. The network
meta-analyses were performed through a Bayesian hierarchical random-effects model analysis. The log odds ratio
(LOR) effect measures were used for dichotomic variables, while the standardized mean difference (SMD) for the
continuous variables.
Results: Data from 2220 procedures (36 articles) were retrieved. The median follow-up was 36 (24 to 60) months.
The ANOVA test found good baseline comparability between symptoms duration, age, sex and body mass index.
AMIC resulted in higher Lysholm score (SMD 3.97) and Tegner score (SMD 2.10). AMIC demonstrated the lowest
rate of failures (LOR −0.22) and the lowest rate of revisions (LOR 0.89). As expected, MFX reported the lower rate of
hypertrophy (LOR −0.17) followed by AMIC (LOR 0.21). No statistically significant inconsistency was found in the
comparisons.
Conclusion: AMIC procedure for focal chondral defects of the knee performed better overall at approximately 3
years’ follow-up.
Keywords: Knee, Chondral defects, Autologous chondrocyte implantation, Osteochondral autograft transplantation,
Autologous matrix-induced chondrogenesis
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Introduction
Focal chondral defects of the knee are common [1].
Avascularity and hypocellularity, along with minimal
metabolic activity of cartilage, lead to a limited self-
repair capability [2–4]. Chondral defects represent one
of the major challenges for orthopaedic surgeons [5]. If
left untreated, they negatively impact patient quality of
life, reducing their sporting activities and resulting in
premature osteoarthritis [6–8]. Knee chondral defects
are 20% more common in athletes [9], increasing up to
50% in those who underwent ACL reconstructive sur-
gery [10, 11]. Symptomatic knee chondral defects often
require surgery. Microfractures (MFX) represent the
traditional approach to these lesions [12]. During osteo-
chondral autograft transplantation (OAT), single or mul-
tiple autologous osteochondral grafts are harvested from
a donor site and transplanted into the chondral defect
[13]. Another surgical technique, namely autologous
chondrocyte implantation (ACI), has been in use since
1994 [14]. At ACI, a sample of hyaline cartilage is har-
vested from a non-weightbearing zone of the distal
femur and the chondrocytes are expanded in vitro. In
the first generation (periosteal ACI or pACI), expanded
chondrocytes are injected into the defect beneath an au-
tologous periosteal membrane [15]. In the second gener-
ation (collagenic ACI or cACI), the periosteal membrane
is replaced by a collagenic membrane [16]. In the third
generation (matrix-induced ACI or mACI), harvested
chondrocytes are directly cultivated over a membrane
that will then be used to cover the defect [17]. Recently,
autologous matrix-induced chondrogenesis (AMIC) has
been proposed to manage chondral defect [18, 19]. In
AMIC, following MFX of the chondral defect, a mem-
brane is used to cover the lesion in a single step surgery
[8, 20]. AMIC exploits the regenerative potential of
bone-marrow derived cells. Given the complexity of
these injuries, and the number of surgical techniques for
knee chondral defects, a Bayesian network meta-analysis
was conducted to compare these strategies for the surgi-
cal management of focal chondral defects of the knee at
midterm follow-up. The purpose of the present study




This Bayesian network meta-analysis was conducted ac-
cording to the PRISMA extension statement for report-
ing of systematic reviews incorporating network meta-
analyses of health care interventions [21]. The PICOT
framework was preliminary pointed out:
 P (Problem): knee chondral defect
 I (Intervention): surgical management
 C (Comparison): pACI, cACI, mACI, AMIC, OAT,
MFX
 O (Outcomes): clinical scores and complications
 T (Timing): ≥ 12 months follow-up
Data source and extraction
Two authors (**;**) independently conducted the litera-
ture search. PubMed, Google Scholar, Embase and Sco-
pus databases were accessed in July 2021. The following
keywords were used in the database search bar using the
Boolean operators AND/OR: chondral, cartilage, articu-
lar, damage, defect, injury, chondropathy, knee, pain,
periosteum, membrane, matrix-induced, autologous,
chondrocyte, autograft, transplantation, implantation,
mACI, pACI, cACI, AMIC, OAT, cylinder, osteochondral,
transplantation, autologous matrix-induced chondrogen-
esis, microfractures, mosaicplasty, management, surgery,
outcomes, revision, failures, hypertrophy. No time con-
strains were set for the search. The same authors
screened separately the resulting articles for inclusion.
The full-text of the articles of interest was accessed. A
cross reference of the bibliography of the full-text arti-
cles was conducted. Disagreements were solved by a
third author (**).
Eligibility criteria
All the clinical trials that compare two or more surgical
interventions for knee chondral defects were accessed.
Given the authors’ language abilities, articles in English,
German, Italian, French and Spanish were eligible. Only
prospective studies levels I to II of evidence, according
to Oxford Centre of Evidence-Based Medicine [22], were
considered. Only studies focusing on AMIC, OAT, MFX
and ACI were considered in the present investigation.
Only studies that clearly stated the surgical procedures
were included. Studies involving patients with end-stage
joint osteoarthritis were not eligible, nor were those in-
volving patients with kissing lesions. Only studies report-
ing data from procedures in knee with a minimum 12
months follow-up were eligible. Animals and computa-
tional studies were not considered. Studies augmenting
the intervention with less committed cells (e.g. mesen-
chymal stem cells) were not considered. Missing quanti-
tative data under the outcomes of interest warranted the
exclusion from this study.
Outcomes of interest
Two authors (**;**) separately performed data extraction.
Study generalities (author, year, journal, type of study)
and patients’ baseline demographic information were ex-
tracted (number of samples and related mean BMI and
age, duration of the symptoms, duration of the follow-
up, percentage of female). For every study, data concern-
ing the International Knee Documentation Committee
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(IKDC) [23], Tegner Activity Scale [24] and Lysholm Knee
Scoring Scale [25] at last follow-up was collected. Data re-
garding complications were also collected: hypertrophy,
rate of failures and revisions. Failure was defined as pain
and/or catching symptoms recurrence, partial or complete
displaced delamination at MRI or arthroscopy [26–28].
Methodology quality assessment
The methodological quality assessment was performed
by two authors (**;**). The risk of bias graph tool of the
Review Manager Software (The Nordic Cochrane Col-
laboration, Copenhagen) was used. The following risks
of bias were evaluated: selection, detection, reporting, at-
trition and other source of bias.
Statistical analysis
The statistical analysis was performed by the main au-
thor (**). The STATA Software/MP (StataCorporation,
College Station, TX, USA) was used for the statistical
analyses. To assess demographic baseline, the Shapiro-
Wilk test has been performed to investigate data distri-
bution. For parametric data, mean and standard devi-
ation were evaluated. The baseline comparability was
assessed using analysis of variance (ANOVA), with P
values > 0.1 considered satisfactory. For non-parametric
data, median and interquartile were evaluated. The base-
line comparability was assessed by the Kruskal-Wallis
test, with P values > 0.1 considered satisfactory. The net-
work meta-analyses were performed through the
STATA routine for Bayesian hierarchical random-effects
model analysis. The inverse variance method was used
for all the comparisons. The log odds ratio (LOR) effect
measures were used for dichotomic variables, while the
standardized mean difference (SMD) for the continuous
variables. The overall inconsistency was evaluated
through the equation for global linearity via the Wald
test. If P value > 0.1, the null hypothesis could not be
rejected, and the consistency assumption is accepted at
the overall level of each treatment. All the variables were
compared in the network analyses against a fictitious
group control: no event for binary comparisons and
maximal value of score for continuous endpoints. Both
confidence (CI) and percentile (PrI) intervals were set at




The literature search resulted in 903 articles. Of them,
207 were duplicates. A further 641 articles did not
match the inclusion criteria: poor level of evidence or
not comparative study (N = 407), not focused on knee
(N = 197), reported short follow-up (N = 9), combined
with stem cells (N = 11) and language limitations (N =
2). A further 15 articles were excluded since they did
not clearly specify the surgical procedure or the eligibil-
ity criteria. A further 19 studies were not considered be-
cause they did not report quantitative data under the
outcomes of interest. This left 36 comparative studies:
22 RCTs and 14 non-RCTs. The literature search results
are shown in Fig. 1.
Methodological quality assessment
Given the predominance of RCTs (22 of 36 studies), the
risk to selection bias was low. The risk of selection bias
of the allocation concealment was very low. Given the
overall lack of blinding, the risk of detection bias was
moderate to high. The risk of attrition and reporting bias
were low, as were the risks of other biases. Concluding,
the overall review authors’ judgements about each risk
of bias item scored low, attesting to this study a good
methodological assessment. The risk of bias graph is
shown in Fig. 2.
Patient demographics
Data from 2220 procedures were retrieved. The mean
duration of symptoms before the index surgery was 44
(25 to 86.5) months. Thirty-six percent (799 of 2210)
were women. The median age of the patients was 33.9
(30 to 37) years, while the median BMI was 25.3 (25 to
26) kg/m2. The mean defect size was 3.7 ± 1.2 cm2. The
median follow-up was 36 (24 to 60) months. The
ANOVA test found good between studies baseline com-
parability in terms of mean duration of symptoms, age,
BMI, gender, defect size and preoperative VAS, Tegner,
Lysholm and IKDC (P > 0.0.5). Generalities of the study
are shown in Table 1, while the within studies baseline
is shown in greater detail in Table 2.
Outcomes of interest
AMIC reported higher Lysholm score (SMD 3.97; 95%
CI −10.03 to 17.98) and Tegner score (SMD 2.10; 95%
CI −3.22 to −0.98). No statistically significant heterogen-
eity was found concerning these two endpoints (P > 0.1).
Statistically significant inconsistency was found for the
comparison IKDC; therefore, no further considerations
can be inferred. Edge, funnel and interval plots of the
Lysholm and Tegner scores are shown in Fig. 3.
Complications
AMIC demonstrated the lowest rate of failures (LOR
−0.22; 95% CI −2.09 to 1.66) and the lowest rate of revi-
sions (LOR 0.89; 95% CI −0.81 to 2.59). As expected,
MFX showed the lowest rate of hypertrophy (LOR
−0.17; 95% CI −3.00 to 2.66) followed by AMIC (LOR
0.21; 95% CI −1.42 to 1.84). No statistically significant
inconsistency was found concerning these two endpoints
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Fig. 2 Methodological quality assessment: Cochrane risk of bias graph
Fig. 1 Flow chart of the literature search
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(P > 0.1). Edge, funnel and interval plots of complica-
tions are shown in detail in Fig. 4.
Discussion
According to the present Bayesian network meta-
analysis, AMIC procedure for the management for chon-
dral defects of the knee performed better overall at ap-
proximately 3 years’ follow-up. Among the ACI
procedures, mACI performed better. Patients undergo-
ing pACI reported the highest rate of graft hypertrophy,
while MFX performed worst overall.
To the best of our knowledge, only Riboth et al. in
2016 [29] conducted a Bayesian network meta-analysis
on surgical strategies for chondral defect of knee. Their
study was based on 15 RCTs, involving 855 procedures.
In the present study, the number of procedures was
greater, as we identified for analysis 21 RCTs and 14
prospective cohort studies with level of evidence II. Dif-
ferently to Riboth et al. [29], we also implemented the
analyses including the rate of failure, included AMIC
procedures and analysed separately the results of the
Tegner and Lysholm scores. The current literature lacks
head-to-head studies that compared AMIC with other
surgical techniques for the management of knee chon-
dral defects. AMIC is a single stage technique that
avoids the harvesting of non-weightbearing cartilage,
cells culture and expansion, exploiting the potential of
autologous bone marrow-derived mesenchymal stem
cells (MSCs). The nature of the membrane used for
AMIC is the same of mACI. Fossum et al. [30]
Table 2 Patient demographic at baseline
Treatment AMIC (N = 103) cACI (N = 253) mACI (N = 761) MFX (N = 619) OAT (N = 124) pACI (N = 319)
Follow-up (months) 56.0 ± 34.1 59.7 ± 42.0 44.9 ± 18.2 45.7 ± 40.6 73.0 ± 46.6 75.4 ± 58.7
Female (%) 29.2 ± 14.9 43.0 ± 20.1 33.8 ± 14.4 37.2 ± 17.4 35.3 ± 7.6 37.7 ± 16.7
Mean age 36.3 ± 6.1 29.0 ± 9.3 32.7 ± 7.3 34.9 ± 8.4 26.0 ± 7.6 31.1 ± 2.6
Mean BMI 27.5 ± 0.2 24.0 ± 1.2 24.8 ± 1.2 25.8 ± 0.9 26.1 ± 1.1 24.0 ± 1.3
defect size (cm2) 3.4 ± 0.9 4.8 ± 0.7 4.2 ± 1.1 2.7 ± 0.9 3.1 ± 0.4 3.9 ± 1.4
Symptoms 83.6 ± 31.0 64.8 ± 30.2 30.6 ± 10.1 23.5 47.4 ± 27.1
VAS (0–10) 6.1 ± 0.5 5.9 ± 0.5 6.3 ± 0.4 6.1 4.8
Tegner score 4.5 ± 0.3 3.1 ± 1.6 2.4 ± 0.6 2.7 3.4 ± 1.0
Lysholm score 68.8 ± 5.0 53.6 ± 1.6 61.7 ± 13.7 53.5 ± 2.2 53.2 56.9 ± 6.3
IKDC score 47.0 36.3 37.7 ± 6.9 36.0 ± 6.5 46.2 ± 8.3
Fig. 3 Results of Tegner and IKDC scores. The edge plot (left) showed direct and indirect comparisons; greater asymmetries of estimated effects
in the funnel plot (middle) correlated with higher risk of bias; the interval plot (right) ranked the final effects of the network comparisons
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comparing 20 patients treated with AMIC versus 21 pa-
tients with cACI, at 2 years’ follow-up, reported no sig-
nificant differences between the two techniques in terms
of Knee injury and Osteoarthritis Outcome Score
(KOOS), Lysholm, VAS and rate of TKA. Previous stud-
ies have compared AMIC versus MFX for knee chondral
defects. Volz et al. [31] compared AMIC versus MFX at
5 years postoperatively. AMIC was an effective cartilage
repair procedure with stable clinical results and signifi-
cantly greater outcome scores than the MFX group [31].
Similar results were found by Chung et al. [32] and An-
ders et al. [33] at 2 years’ follow-up.
The present Bayesian network meta-analysis certainly
has limitations. The limited number of studies and con-
sequently procedures is an important limitation. Chon-
drocyte culture and expansion methods for ACI among
the included studies are heterogeneous. We included all
types of surgical approach (arthroscopy, mini-open,
arthrotomy), membrane type (collagenic or hyaluronic)
and fixation (glue, fibrin, both, none). The influence of
these factors has not been yet fully clarified, and further
studies are required. Several comparative trials concern-
ing MSCs augmentation for knee chondral defects have
been published [34–38]. While MSCs seem to hold great
potential for musculoskeletal systems [39–41], to over-
come current limitations to clinical translation is still
challenging and a deeper understanding of the biological
background to optimize tissue neogenesis is required.
Thus, given these limitations, studies concerning MSC
augmentation were not considered for inclusion. Two
studies [42, 43] performed membrane-assisted autolo-
gous chondrocyte transplantation (mACT). In the
mACT technique, chondrocytes are cultivated and ex-
panded into a membrane in the same fashion of mACI.
The chondrocyte-loaded membrane is then carefully
transplanted to fill the defect with custom-made instru-
ments in a full-arthroscopic fashion [44, 45]. We in-
cluded data from this technique in the mACI group and
did not analyse them separately. Given the lack of data,
it was not possible to analyse the aetiology of chondral
Fig. 4 Results of complications. The edge plot (left) showed direct and indirect comparisons; greater asymmetries of estimated effects in the
funnel plot (middle) correlated with higher risk of bias; the interval plot (right) ranked the final effects of the network comparisons
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defects as separate data sets. Moreover, almost all the in-
cluded studies did not analyse primary and revision sur-
geries as separate events. Similarly, most of studies
reported data over multiple locations, without differenti-
ation between patella, trochlear, condylar and tibial de-
fects. Finally, many authors combined these techniques
with other surgical intervention, such as osteotomy, tib-
ial tubercle transfer and meniscal procedures, and data
were not presented separately. Given these limitations,
results from the present study should be interpreted
with caution. Current evidence concerning chondral
procedures augmented with mesenchymal stem cells
(MSCs) is still very limited [34–38, 46–55]. The best de-
livery protocol is still debated, and several different pro-
cedures are described through different methodologies
with a variable degree of invasiveness, from arthroscopy
to mini arthrotomy, or formal arthrotomy [34–36, 46–
50, 52–54]. Most articles investigating chondral proce-
dures augmented with MSCs referred to a small sample
size and limited length of the follow-up, and the size and
location of the chondral defect and the cell delivery
protocol are heterogeneous, precluding statistical ana-
lysis [1, 56–61]. Moreover, meniscectomy, synovectomy,
anterior cruciate ligament repair and high tibial osteot-
omy were often performed concomitantly [34–38, 46,
50, 52, 53]. Several MSCs sources, culture, expansion
and implantation modalities have been described, but
seldom compared to one another. Thus, given these lim-
itations, chondral procedures augmented with MSCs
were not included. Future studies should overcome these
limitations to give new insights and more reliable
results.
Conclusion
AMIC procedure as management for focal chondral de-
fects of the knee performed better overall at approxi-
mately 3 years’ follow-up.
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